Results 61 to 70 of about 310,541 (331)

Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions

Journal of Hepatocellular Carcinoma, 2021
Francesca Fornari,1,2 Catia Giovannini,1,3 Fabio Piscaglia,4,5 Laura Gramantieri4 1Centre for Applied Biomedical Research - CRBA, University of Bologna, St.
Fornari F, Giovannini C, Piscaglia F, Gramantieri L   +3 more
doaj  

Domain associated with zinc fingers‐containing NF90‐NF45 complex inhibits m6A modification of primary microRNA by suppressing METTL3/14 activity

FEBS Open Bio, EarlyView.
NF90–NF45 functions as a negative regulator of methyltransferase‐like 3/14 (METTL3/14)‐mediated N6‐methyladenosine (m6A) modification on primary microRNAs (pri‐miRNAs). NF90–NF45 binds to anti‐oncogenic pri‐miRNAs and inhibits their m6A modification, thereby suppressing the biogenesis of anti‐oncogenic miRNAs.
Takuma Higuchi, Shunsuke Morioka, Keiko Morisawa, Kazutsugu Matsukawa, Shingo Ashida, Takeshi Suzuki, Shuji Sakamoto   +6 more
wiley   +1 more source

Transcatheter Arterial Chemoembolization with Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma: Recommended Selection for Small-Caliber (<100 μm) Beads

Journal of Hepatocellular Carcinoma, 2021
Wei-Chou Chang,1 Hsian-He Hsu,1 Sung-Hua Chiu,1 Wen-Yen Huang,2 Cheng-Hsiang Lo,2 Hsuan-Hwai Lin,3 Pei-Ching Huang,4 Yu-Lueng Shih,3 Yung-Liang Wan4 1Department of Radiology, Tri-Service General Hospital and National Defense Medical Center, Taipei ...
Chang WC, Hsu HH, Chiu SH, Huang WY, Lo CH, Lin HH, Huang PC, Shih YL, Wan YL   +8 more
doaj  

JNK signalling in cancer: In need of new, smarter therapeutic targets [PDF]

, 2013
Copyright © 2013 The British Pharmacological Society. This is the accepted version of the following article: Bubici, C. and Papa, S. (2014), JNK signalling in cancer: in need of new, smarter therapeutic targets.
Adams, Ahmed, Anbalagan, Annunziata, Antonyak, Bain, Barbarulo, Barr, Behrens, Bennett, Bharti, Bogoyevitch, Bogoyevitch, Borsello, Bost, Carboni, Cazanave, Cellurale, Cellurale, Cellurale, Chang, Chang, Chauhan, Chen, Chen, Chen, Chen-Deutsch, Cho, Choi, Chromik, Cilloni, Cripe, Cui, Cui, Das, Davis, Deininger, Dérijard, Eferl, Estey, Farazi, Ferrandi, Finegan, Fuchs, Gaillard, Gao, Gao, Gilmore, Goenka, Graff, Gururajan, Hagiwara, He, Heo, Hess, Hideshima, Hideshima, Hideshima, Hirosumi, Ho, Huang, Hui, Hunot, Jaeschke, Jagtap, Jemal, Johnson, Kamenecka, Kaneto, Kaoud, Ke, Keats, Kersting, Kuan, Kuperwasser, Li, Llovet, Lloyd, LoGrasso, Luedde, Maclean, Maeda, Mamay, Manning, Manning, Min, Mucha, Murati, Nagata, Nateri, Ngoei, Ngoei, Nitta, Oleinik, Owens, Papa, Papa, Plantevin Krenitsky, Qiu, Raitano, Reinecke, Ricard, Rodrigues, Ronaldson, Roy, Sabapathy, Sakurai, Schramek, Seki, She, Siddiqui, Smeal, Srivastava, Stebbins, Su, Su, Szczepankiewicz, Takahashi, Tong, Tournier, Tsuiki, Waetzig, Wagner, Wang, Wang, Webster, Whitmarsh, Whitmarsh, Yamamoto, Yan, Yang, Yao, Yoon, Yoshida, Zhang, Zhang, Zhang, Zhang   +137 more
core   +2 more sources

A Single‐Metal‐Doped Nanoplatform for Ferroptosis‐Driven cGAS‐STING Pathway Activation in Hepatocellular Carcinoma Immunotherapy

Advanced Functional Materials, EarlyView.
The cGAS‐STING pathway boosts HCC antitumor immunity but lacks specific activation. Nanoplatform ZMRPF induces HCC ferroptosis via lipid ROS, releasing mtDNA. It synergizes with ZMRPF‐released Mn2⁺ to activate cGAS‐STING, amplifies antigen‐presenting cell activity, reverses HCC immunosuppression, and enables robust systemic antitumor immunity ...
Yuchen Zhang, Shuang Feng, Jie Luo, Kaige Xu, Junfeng Guo, Xingyue Zhang, Mengxue Yuan, Qiang Luo, Yu Huang, Chaoqiang Fan, Kibret Mequanint, Donghui Zhu, Malcolm Xing, Shiming Yang   +13 more
wiley   +1 more source

circ-CFH promotes the development of HCC by regulating cell proliferation, apoptosis, migration, invasion, and glycolysis through the miR-377-3p/RNF38 axis

Open Life Sciences, 2022
Circular RNAs (circRNAs) have previously been confirmed to function as vital regulators in multiple human cancers, including hepatocellular carcinoma (HCC). This study aimed to clarify the role and underlying molecular mechanisms of circ-CFH in HCC. circ-
Chen Zengyin, Du Juan, Yang Chen, Si Guangju, Chen Yuxin   +4 more
doaj   +1 more source

Synthetic Nanobiology Actuated Lipometabolic Cell Factory for Autologous Tumor Immunotherapy

Advanced Functional Materials, EarlyView.
FA plays a crucial role in the interaction between tumor cells and the tumor microenvironment, especially for the immune response. A biocatalytic immunoenhancement strategy is developed to boost antitumor immunity by FA metabolic orientation to ceramide. Through the design of this delicate catalytic immunoenhancement strategy, the synthetic nanobiology
Shoujie Zhao, Yejing Zhu, Hengchao Yu, Jun Zhu, Bo Wang, Yu Qiao, Zhimin Tian, Junlong Zhao, Lei Liu   +8 more
wiley   +1 more source

90Y-/166Ho- ‘Radiation lobectomy’ for liver tumors induces abnormal morphology and impaired drainage of peritumor lymphatics

JHEP Reports
Background & Aims: High-dose unilobar radioembolization, or ‘radiation lobectomy’ (RL), is an induction therapy that achieves contralateral future liver remnant hypertrophy while simultaneously irradiating the tumor.
Daan Andel, Lotte van den Bent, Marnix Gerard Ernest Hendrik Lam, Maarten Leonard Johannes Smits, Isaac Quintus Molenaar, Joep de Bruijne, Miangela Marie Laclé, Onno Kranenburg, Inne Hildbrand Max Borel Rinkes, Jeroen Hagendoorn   +9 more
doaj   +1 more source

Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. [PDF]

, 2019
Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma (HCC).
Coben, Robert M., Conn, Mitchell I., DiMarino, Anthony J., Hann, Hie-Won, Kroop, Howard, Martin, Aaron, Prieto, Jorge, Shinn, Brianna J.   +7 more
core   +1 more source

Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE) : study protocol for a randomized controlled trial [PDF]

, 2012
Background: Hepatocellular carcinoma is a primary malignant tumor of the liver that accounts for an important health problem worldwide. Only 10 to 15% of hepatocellular carcinoma patients are suitable candidates for treatment with curative intent, such ...
Al Younis, Imad, Coenraad, Minneke J, Defreyne, Luc, Lam, Marnix GEH, Lambert, Bieke, Seinstra, Beatrijs A, van den Bosch, Maurice AAJ, van Erkel, Arian R, van Erpecum, Karel J, van Hoek, Bart, Van Vlierberghe, Hans, Verkooijen, Helena M   +11 more
core   +1 more source